Alymsys®, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, …

Do not administer Alymsys® until at least 28 days following major surgery and until adequate wound healing. This is an abbreviated summary of the approved indications and dosing schedule.

ALYMSYS® (bevacizumab maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous …

Alymsys (bevacizumab-maly) is an anti-angiogenic therapy used to block the blood supply that feeds cancer tumors and prevents it from growing. This is different from chemotherapy, which …

ALYMSYS® (bevacizumab maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous …

Discover comprehensive support and effective treatment options for Non Hodgkin Lymphoma with Alymsys®. From personalized therapies to expert guidance

Please see next page for additional Important Safety Information and visit Alymsys.us for full Prescribing Information. HCPCS, Healthcare Common Procedure Coding System; NDC, …

The Stella study, confirmed the clinical similarity in terms of eficacy, safety and immunogenicity of Alymsys® and Avastin®, supporting the clinical safety and eficacy of Alymsys® treatment.

Both Alymsys® and Avastin® are highly pure products with > 95% purity measured by size exclusion chromatography. Low levels of aggregates are present in both products with slightly …

ALYMSYS® (bevacizumab maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous …